These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 26959061)

  • 21. Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®.
    Kollewe K; Mohammadi B; Köhler S; Pickenbrock H; Dengler R; Dressler D
    J Neural Transm (Vienna); 2015 Mar; 122(3):427-31. PubMed ID: 25059456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin type-A preparations are not the same medications - clinical studies (Part 2).
    Sławek J; Bogucki A; Bonikowski M; Car H; Dec-Ćwiek M; Drużdż A; Koziorowski D; Sarzyńska-Długosz I; Rudzińska M
    Neurol Neurochir Pol; 2021; 55(2):141-157. PubMed ID: 33797748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
    Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
    Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of long-term botulinum toxin treatment for acquired cervical dystonia: a 25-year follow-up.
    Petracca M; Lo Monaco MR; Ialongo T; Di Stasio E; Cerbarano ML; Maggi L; De Biase A; Di Lazzaro G; Calabresi P; Bentivoglio AR
    J Neurol; 2023 Jan; 270(1):340-347. PubMed ID: 36068376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Applications of botulinum toxin in Neurology].
    Garcia-Ruiz PJ
    Med Clin (Barc); 2013 Jul; 141(1):33-6. PubMed ID: 23434466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study.
    Peyronnet B; Castel-Lacanal E; Roumiguie M; Even L; Marque P; Soulié M; Rischmann P; Game X
    Neurourol Urodyn; 2017 Mar; 36(3):734-739. PubMed ID: 27037973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity.
    Camões-Barbosa A; Ribeiro IM; Medeiros L
    Acta Med Port; 2020 Nov; 33(11):761-764. PubMed ID: 31759399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Botulinum toxin therapy for focal dystonia].
    Hahn K; Niklai E; Garzuly F; Szupera Z
    Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
    Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
    Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm.
    Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
    Eur J Neurol; 2009 Mar; 16(3):392-8. PubMed ID: 19364366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.
    Esquenazi A; Albanese A; Chancellor MB; Elovic E; Segal KR; Simpson DM; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():115-28. PubMed ID: 23220492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG; Tyrrell EG; Grosset KA
    J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New trends in the science of botulinum toxin-A as applied in dystonia.
    Pickett A; Rosales RL
    Int J Neurosci; 2011; 121 Suppl 1():22-34. PubMed ID: 21244295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.
    Chen JJ; Dashtipour K
    Pharmacotherapy; 2013 Mar; 33(3):304-18. PubMed ID: 23400888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cost-utility analysis of two formulations of botulinum toxin type A in the treatment of blepharospasm and cervical dystonia in Spain].
    Sanz-Granda A; Marti MJ; Catalan MJ
    Rev Neurol; 2018 Dec; 67(12):465-472. PubMed ID: 30536360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
    Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
    Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Near-Infrared Transflectance Spectroscopy Discriminates Solutions Containing Two Commercial Formulations of Botulinum Toxin Type A Diluted at Recommended Volumes for Clinical Reconstitution.
    Currà A; Gasbarrone R; Bonifazi G; Serranti S; Fattapposta F; Trompetto C; Marinelli L; Missori P; Lendaro E
    Biosensors (Basel); 2022 Apr; 12(4):. PubMed ID: 35448275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical applications of a new botulinum toxin.
    Hexsel D; Spencer JM; Woolery-Lloyd H; Gilbert E
    J Drugs Dermatol; 2010 Mar; 9(3 Suppl):s31-7. PubMed ID: 20361474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.